Cargando…
Gadoxetic Acid-Based MRI for Decision-Making in Hepatocellular Carcinoma Employing Perfusion Criteria Only—A Post Hoc Analysis from the SORAMIC Trial Diagnostic Cohort
The value of gadoxetic acid in the diagnosis of hepatocellular carcinoma (HCC), based on perfusion criteria, is under dispute. This post-hoc analysis of the prospective, phase II, randomized, controlled SORAMIC study compared the accuracy of gadoxetic acid-enhanced dynamic magnetic resonance imaging...
Autores principales: | Seidensticker, Max, Steffen, Ingo G., Bargellini, Irene, Berg, Thomas, Benito, Alberto, Gebauer, Bernhard, Iezzi, Roberto, Loewe, Christian, Karçaaltincaba, Musturay, Pech, Maciej, Sengel, Christian, van Delden, Otto, Vandecaveye, Vincent, Zech, Christoph J., Ricke, Jens |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870455/ https://www.ncbi.nlm.nih.gov/pubmed/35200551 http://dx.doi.org/10.3390/curroncol29020051 |
Ejemplares similares
-
Correlation of liver enhancement in gadoxetic acid–enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial
por: Öcal, Osman, et al.
Publicado: (2021) -
Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma
por: Ricke, Jens, et al.
Publicado: (2020) -
Non-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression
por: Öcal, Osman, et al.
Publicado: (2022) -
Extrahepatic Disease in Hepatocellular Carcinoma: Do We Always Need Whole-Body CT or Is Liver MRI Sufficient? A Subanalysis of the SORAMIC Trial
por: Geyer, Thomas, et al.
Publicado: (2022) -
Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial
por: Öcal, Osman, et al.
Publicado: (2021)